Cardiovascular Therapy Market pertain to the blood vessel and heart conditions that can affect the heart valve, cardiac muscle with the circulation system that monitors the blood flow and distribution and the cardiac electrical system which controls the heart rhythm and rate. These complex systems are taken care of by the cardiovascular therapy device market owing to the increasing number of global population being affected by the above mentioned diseases. The cardiovascular therapy market is expected to grow in the forecast period owing to introduction of improved technologies and devices that provide solutions for Cardio vascular diseases.
Request a Sample PDF Copy of This Report @ https://www.millioninsights.com/industry-reports/cardiovascular-therapy-market/request-sample
The key driving factors responsible for the growth of Cardiovascular
Therapy market :
Growth in the global
cardiovascular therapy market is attributed to factors owing to increasing
worldwide prevalence of chronic CVDs and a higher percentage of aging
population. Improvements in treatment capabilities in developing markets owing
to technological advancements and innovation is expected to have a positive
impact on the demand for cardiovascular thereupatic devices in the medical and
healthcare sector. Technological advent with respect to therapeutic devices
includes development of extended product life, smaller devices, and surgical
improvements. Increase in demand is also driven by increased risk factors
(diabetes, smoking, obesity, and hypertension) among people
Key application of in
cardiovascular therapy is the hybrid operation rooms market that emphasizes on
minimal invasive surgeries. Therefore, Global cardiovascular therapy market is
expected to witness a growth owing to increasing demand for minimally invasive
surgeries. However, high costs for treatment and safety concerns are major challenges
before the market. Cardiovascular
therapy comprises of Anti-hypertensives, anticoagulants, anti-arrhythmic,
Antithrombotics and Antidyslipidemics. Global cardiovascular market had a sale
of $170bn in 2010 and is expected to have a positive growth in the forecast
period. With a share of 40% of the total market, the US continued to be the
market leader in this segment. Although there has been a decline in the sales
of cardiovascular therapy market due to saturation of key drug categories and
an increased generic presence, the US witnessed a steady growth in the market
since 2009 and is expected to continue the same trend.
Antihypertensives remained the
largest drug class in the past few years with global sales of over $37.6bn and
an overall market share of over 22%. Angiotensin receptor blockers (ARBs) is
expected to remain the most prescribed therapeutic class within
antihypertensives driven by key brands such as Cozaar, Diovan, and Avapro.
Novartis’s Diovan is the market leader with $3.6bn in sales and the second
largest being Benicar with sales of $2.9bn.
The anticoagulants segment is expected to witness significant activity
over the forecast period owing to introduction of new drugs such as
BoehringerPradaxa/Rendix, Ingelheim's, Bayer-Schering/J&J's, BMS/Pfizer's
apixaban, Xarelto and Eli Lilly/Daiichi's Effient which are subjected to
intensive R&D activities. Since most of the factor Xa inhibitors are in
oral form, they are expected to cater to a wider market.
Crestor is expected to witness a
steady growth in the market owing to positive trial results that has the
capability to strengthen its market position. The positive trial data is likely
to result in higher number of recommendations for cholesterol treatment and
capture more number of patients with cardiovascular disorders GlaxoSmithKline's
(GSK) is expected to have the highest growth among leading players owing to the
acquisition of Reliant Pharma. Addition of new drugs such as Lovaza in GSKs
portfolio is a key factor that can drive the growth in this segment In 2010, Antithrombotics recorded a sale of
over $18.7bn and a market share of over 11%. Antithrombitics are forecasted to
witness a strong growth in the next seven years owing to increase in the commercialization
of recently approved products such as Xarelto, Pradaxa and launch of
Pfizer/BMS’s apixabanBetter bleeding profile and superior effectiveness of
Brilinta (ticagrelor) over Plavix make it major antithrombotic drug that could
be a key player in acute coronary syndrome (ACS).
View Full Table of Contents of This Report @ https://www.millioninsights.com/industry-reports/cardiovascular-therapy-market
No comments:
Post a Comment